Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of early rheumatoid arthritis.~* Methotrexate (MTX) naive.~* Active early rheumatoid arthritis at the time of enrollment.~Exclusion Criteria:~* Previous or current treatment with etanercept, other tumor necrosis factor-alpha (TNF) inhibitors, or other biologic agents.~* Concurrent treatment with any disease-modifying anti-rheumatoid drugs (DMARD), within 4 weeks before baseline.~* Concurrent treatment with more than 1 non-steroidal anti-inflammatory drug (NSAID) at baseline.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): etanercept + methotrexate; etanercept + methotrexate

Based on this trial design, predict the completion outcome and termination type (if applicable).